Clinical trials
Withdrawn trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
490 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 14 |
| 2012 | 7 |
| 2013 | 9 |
| 2014 | 11 |
| 2015 | 25 |
| 2016 | 22 |
| 2017 | 36 |
| 2018 | 37 |
| 2019 | 30 |
| 2020 | 36 |
| 2021 | 46 |
| 2022 | 43 |
| 2023 | 36 |
| 2024 | 64 |
| 2025 | 31 |
| 2026 | 26 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 490 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 33 |
| Children's Hospital of Fudan University | 19 |
| Fuda Cancer Hospital, Guangzhou | 18 |
| Zeng Changhao | 17 |
| Beijing Boren Hospital | 13 |
| Shandong University | 10 |
| Peking University People's Hospital | 8 |
| Fudan University | 7 |
| Ruijin Hospital | 7 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 24 |
| Lung Neoplasms | 17 |
| Colorectal Neoplasms | 14 |
| Breast Neoplasms | 13 |
| COVID-19 | 13 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Recurrence | 13 |
| Purpura, Thrombocytopenic, Idiopathic | 11 |
| Esophageal Neoplasms | 9 |
| Lymphoma, B-Cell | 9 |
Trials
Showing 51 to 75 of 490. Each trial links to its page on Pharma Observatory.
390 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.